Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil

Transplantation

Volumn 66, Issue 5, 1998, Pages 593-598

  Paterson, David L ^a   Singh, Nina ^a,b   Panebianco, Annunziata ^a   Wannstedt, Cheryl F ^a   Wagener, Marilyn M ^a   Gayowski, Timothy ^a   Marino, Ignazio R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; GRAFT VERSUS HOST REACTION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS HEPATITIS; VIRUS REACTIVATION;

COHORT STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; PENNSYLVANIA; PROSPECTIVE STUDIES; TACROLIMUS;

EID: 0032530706     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199809150-00007     Document Type: Article

References (27)

1. Florey HW, Gilliver K, Jennings MA, Sanders AG. Mycophenolic acid: an antibiotic from Penicillium brevicompactum Dierckx. Lancet 1946; i: 46.
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 625.
3. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
4. The Tricontinental Mycophenolate mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
5. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39.
6. Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998; 65: 248.
7. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65: 180.
8. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharmacol Res 1990; 7: 161.
9. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 1993; 685: 309.
10. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil. Clin Transplant 1996; 10: 77.
11. Singh N, Gayowski T, Wagener M, Yu VL. Infectious complications in liver transplant recipients on tacrolimus. Transplantation 1994; 58: 774.
12. Gavlik A, Goldberg MG, Tsaroucha A, et al. Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant Proc 1997; 29: 549.
13. Gavlik A, Demirbas A, Tsaroucha A, et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. Transplant Proc 1997; 29: 2971.
14. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128.
15. Singh N, Gayowski T, Wagener MM, Yu VL. Infectious complications in liver transplant recipients on tacrolimus. Transplantation 1994; 58: 774.
16. Gerna G, Revello MG, Percivalle E, et al. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232.
17. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared to short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994; 120: 375.
18. Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996; 61: 402.
19. Martin P, Munoz SJ, DiBisceglie AM, et al. Recurrence of hepatitis C virus infection after orthotopic liver transplantation. Hepatology 1991; 13: 719.
20. Read AE, Donegan E, Lake JR, et al. Hepatitis C in patients undergoing liver transplantation. Ann Intern Med 1991; 114: 282.
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5: 431.
22. Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophnolate. Transplantation 1997; 64: 1755.
23. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 216.
24. Freeman RB, Tran S, Lee YM, Rohrer RJ, Kaplan MM. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1996; 61: 542.
25. Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother 1997; 41: 156.
26. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J Infect Dis 1997; 175: 901.
27. Danovitch G, Deierhoi M, Ferguson R, et al. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplantation rejection. Transplantation 1996; 61: 722.